Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023
08 Settembre 2023 - 4:02PM
Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the
continuous growing global recognition of its LIBERTY® Robotic
Surgical System, to be presented in an abstract at the Annual
Congress of the Cardiovascular and Interventional Radiological
Society of Europe (CIRSE) on September 9, 2023. The abstract is to
be presented by Professor of Interventional Radiology Vincent
Vidal, M.D. PhD, from the Aix-Marseille University and a Scientific
Advisory Board Member of Microbot.
The abstract and oral presentation, titled
“Performance Evaluation of a Miniature and Disposable Endovascular
Robotic Device” was accepted following a successful pre-clinical
trial with a team of leading European interventional radiologists.
The team expressed their positive experiences and satisfaction from
using the Company’s Robotic Surgery System.
The Company believes that the accumulation of
peer-reviewed data during the pre-clinical studies are invaluable
opportunities to gather leading physicians’ and future users’
insight as it finalizes the necessary steps prior to its expected
First in Human (FIH) clinical trial and the regulatory process with
the FDA in the USA and MDR in Europe.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body.
The LIBERTY® Robotic Surgical System aims to
improve the way surgical robotics are being used in endovascular
procedures today, by eliminating the need for large, cumbersome,
and expensive capital equipment, while reducing radiation exposure
and physician strain. The Company believes the LIBERTY® Robotic
Surgical System’s remote operation has the potential to be the
first system to democratize endovascular interventional
procedures.
Further information about Microbot Medical is
available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of
potential products, including LIBERTY, the outcome of its studies
to evaluate LIBERTY, whether the Company’s core business focus
program and cost reduction plan are sufficient to enable the
Company to continue to focus on its LIBERTY technology while it
seeks additional working capital, any failure or inability to
recruit physicians and clinicians to serve as primary investigators
to conduct regulatory studies which could adversely affect or delay
such studies, uncertainty in the results of pre-clinical and
clinical trials or regulatory pathways and regulatory approvals,
any lingering uncertainty resulting from the COVID-19 pandemic,
need and ability to obtain future capital, and maintenance of
intellectual property rights. Additional information on risks
facing Microbot Medical can be found under the heading “Risk
Factors” in Microbot Medical’s periodic reports filed with the
Securities and Exchange Commission (SEC), which are available on
the SEC’s web site at www.sec.gov. Microbot Medical disclaims any
intent or obligation to update these forward-looking statements,
except as required by law.
Investor Contact:
Michal Efraty+972-(0)52-3044404IR@microbotmedical.com
Grafico Azioni Microbot Medical (NASDAQ:MBOT)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Microbot Medical (NASDAQ:MBOT)
Storico
Da Set 2023 a Set 2024